COST AND HEALTHCARE RESOURCE UTILIZATION (HRU) RESULTING FROM IMMUNE-RELATED ADVERSE EVENTS (IRAES) AMONG PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS (ICIS)

被引：0
|
作者：
Zheng, Y. [1 ]
Kim, R. [2 ]
Yu, T. [1 ]
Dreyfus, J. [3 ]
Gayle, J. A. [3 ]
Wassel, C. L. [3 ]
Phatak, H. [1 ]
George, S. [4 ]
机构：
[1] EMD Serono Inc, Rockland, MA USA
[2] Pfizer Inc, New York, NY USA
[3] Premier Inc, Charlotte, NC USA
[4] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN171
引用
收藏
页码：S469 / S469
页数：1
相关论文
共 50 条
  • [1] Immune-related adverse events (IrAEs) in patients receiving immune checkpoint inhibitors
    Ferrarini, Alessia
    Benfaremo, Devis
    Rossetti, Giulia
    Morgese, Francesca
    Pomponio, Giovanni
    Berardi, Rossana
    Gabrielli, Armando
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18
  • [2] Association of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)
    Riudavets Melia, M.
    Gabriela Sullivan, I.
    Barba Joaquin, A.
    Anguera Palacios, G.
    del Carpio, L. P.
    Molto Valiente, C.
    Camacho Arellano, S. D.
    Moron Asensio, S.
    Gomila Pons, P.
    Andres Granyo, M.
    Castillo Villegas, D.
    Facundo Molas, C.
    Garcia Planella, E.
    Gonzalez Blanco, C.
    Barnadas Molins, A.
    Gich Saladich, I.
    Majem Tarruella, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 509 - 509
  • [3] Real world outcomes of immune-related adverse events (irAEs) among patients receiving immune checkpoint inhibitors (ICIs) in hospital settings
    George, S.
    Zheng, Y.
    Kim, R.
    Yu, T.
    Dreyfus, J.
    Gayle, J. A.
    Wassel, C.
    Phatak, H.
    ANNALS OF ONCOLOGY, 2019, 30 : 522 - 522
  • [4] Frequency of delayed immune-related adverse events (irAEs) in hospitalized patients treated with immune checkpoint inhibitors (ICIs)
    Durbin, Sienna
    Zubiri, Leyre
    Perlman, Katherine
    Molina, Gabriel
    Jacoby, Ted
    Shah, Nishi
    Reynolds, Kerry Lynn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Patterns of immune-related adverse events (irAEs) in adolescent and young adult (AYA) patients with melanoma receiving immune checkpoint inhibitors (ICIs)
    He, Jiasen
    John, Ida
    Afridi, Faraz
    Sun, Mianen
    Wang, Yinghong
    Roth, Michael
    McQuade, Jennifer Leigh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Healthcare resource utilization (HCRU) and costs in patients (pts) with advanced cancer treated with immune checkpoint inhibitors (ICIs) who experienced select immune-related adverse events (irAEs)
    George, S.
    Zheng, Y.
    Bell, E. J.
    Engel-Nitz, N. M.
    White, J. C.
    Lal, L. S.
    Kim, R.
    Krulewicz, S.
    Smith, J.
    Liu, F. X.
    ANNALS OF ONCOLOGY, 2020, 31 : S968 - S969
  • [7] Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy.
    Das, Satya
    Ciombor, Kristen Keon
    Haraldsdottir, Sigurdis
    Pumpalova, Yoanna S.
    Sahin, Ibrahim Halil
    Shyr, Yu
    Chu, Shih-Kai
    Lin, Emily Pei-Ying
    Hsu, Chih-Yuan
    Goff, Laura Williams
    Cardin, Dana Backlund
    Bilen, Mehmet Asim
    Berlin, Jordan
    Wu, Christina
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients
    Giommoni, Elisa
    Giorgione, Roberta
    Paderi, Agnese
    Pellegrini, Elisa
    Gambale, Elisabetta
    Marini, Andrea
    Antonuzzo, Andrea
    Marconcini, Riccardo
    Roviello, Giandomenico
    Matucci-Cerinic, Marco
    Capaccioli, David
    Pillozzi, Serena
    Antonuzzo, Lorenzo
    IMMUNO, 2021, 1 (03): : 253 - 263
  • [9] Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) to predict succeeding onset of immune-related adverse events (irAEs).
    Kizawa, Rika
    Miura, Yuji
    Oda, Yasuhiro
    Nagaoka, Yukiko
    Ozaki, Yukinori
    Kondoh, Chihiro
    Moriguchi, Shuhei
    Takahashi, Yui
    Ogawa, Kazumasa
    Tanabe-Hashimoto, Yuko
    Taniguchi, Shuichi
    Okaneya, Toshikazu
    Kishi, Akiko
    Hayashi, Nobukazu
    Kishi, Kazuma
    Takano, Toshimi
    Masuda, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Eosinophilia during treatment of immune checkpoint inhibitors (ICIs) predicts succeeding onset of immune-related adverse events (irAEs)
    Kizawa, R.
    Miura, Y.
    Oda, Y.
    Nagaoka, Y.
    Masuda, J.
    Ozaki, Y.
    Kondoh, C.
    Moriguchi, S.
    Takahashi, Y.
    Ogawa, K.
    Hashimoto, Y. Tanabe
    Taniguchi, S.
    Okaneya, T.
    Kishi, A.
    Hayashi, N.
    Takaya, H.
    Takano, T.
    ANNALS OF ONCOLOGY, 2019, 30
12345